title: What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us.
abstract: The aborted trial of semagacestat has led some to invoke unanticipated effects of γ-secretase inhibition on formation of amyloid β. However, the many substrates for γ-secretases and the varied biological effects of each of the resultant cleavage products make ascribing causality much more complex than that.
authors.affiliation: Department of Pediatrics, University of Rochester Medical Center, Golisano Children's Hospital, NY, USA.
authors.forename: Nina F
authors.initials: NF
authors.lastname: Schor
mesh_terms: D000409:Alanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000378:metabolism; D053829:Amyloid Precursor Protein Secretases / Q000037:antagonists & inhibitors*; D016229:Amyloid beta-Peptides / Q000378:metabolism; D001381:Azepines / Q000627:therapeutic use*; D057239:Early Termination of Clinical Trials; D006801:Humans
chemical_list: D016229:Amyloid beta-Peptides; D001381:Azepines; C484278:N2-((2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-L-alaninamide; D053829:Amyloid Precursor Protein Secretases; D000409:Alanine